WO2024251659 - DNA-BINDING PROTEIN-A MODULATOR FOR THE TREATMENT OF RENAL ISCHEMIA/REPERFUSION INJURY
National phase entry:
Publication Number
WO/2024/251659
Publication Date
12.12.2024
International Application No.
PCT/EP2024/065192
International Filing Date
03.06.2024
Title **
[English]
DNA-BINDING PROTEIN-A MODULATOR FOR THE TREATMENT OF RENAL ISCHEMIA/REPERFUSION INJURY
[French]
MODULATEUR DE LA PROTÉINE A DE LIAISON À L'ADN POUR LE TRAITEMENT D'UNE LÉSION D'ISCHÉMIE/REPERFUSION RÉNALE
Applicants **
OTTO-VON-GUERICKE-UNIVERSITÄT MAGDEBURG
Inventors
MERTENS, Peter R.
REICHARDT, Charlotte
Priority Data
23178553.6
09.06.2023
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2436 | |
| EPO | Filing, Examination, Granting | 9763 | |
| Japan | Filing, Examination, Granting | 2225 | |
| South Korea | Filing, Examination, Granting | 2097 | |
| USA | Filing, Examination, Granting | 7740 |
Total:
24,261
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present invention relates to a DNA-binding protein-A (DbpA) modulating compound for use in the treatment of an acute kidney injury (AKI). In addition, the present invention relates to a combination of a DbpA modulating compound and a drug different from a DbpA modulating compound for use in the treatment of an acute kidney injury (AKI).[French]
La présente invention concerne un composé de modulation de la protéine A de liaison à l'ADN (DbpA) destiné à être utilisé dans le traitement d'une lésion rénale aiguë (AKI). En outre, la présente invention concerne une combinaison d'un composé de modulation de la DbpA et d'un médicament différent d'un composé de modulation de la DbpA destinée à être utilisée dans le traitement d'une lésion rénale aiguë (AKI).